Zemiglo is contraindicated in patients with a history of serious hypersensitivity reactions, i.e., angioedema or anaphylaxis, to another dipeptidyl peptidase-4 (DPP-4) inhibitor (see Adverse Reactions); Type 1 diabetes or diabetic ketoacidosis.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
